je.st
news
UPDATE 2-Celgene to stop blood cancer trial due to high death rates
2013-07-18 23:40:32| Biotech - Topix.net
Celgene Corp said it will stop a late-stage trial of its blood cancer drug, Revlimid, after it observed a higher number of deaths in elderly leukemia patients taking the drug compared with those on another treatment.
Tags: high
due
rates
update
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||